Scienture Holdings, Inc.
$ 0.40
1.28%
17 Apr - close price
- Market Cap 16,049,200 USD
- Current Price $ 0.40
- High / Low $ 0.40 / 0.37
- Stock P/E N/A
- Book Value 1.73
- EPS -2.70
- Next Earning Report 2026-05-11
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.11 %
- ROE -0.56 %
- 52 Week High 2.60
- 52 Week Low 0.24
About
Scienture Holdings, Inc. (SCNX) is a biotechnology company dedicated to advancing therapeutic solutions for neurological disorders through its innovative drug development pipeline. Leveraging cutting-edge technology and a highly proficient research team, Scienture aims to address significant unmet medical needs while enhancing patient outcomes. The company's unwavering commitment to scientific excellence, regulatory adherence, and strategic partnerships not only fuels its growth prospects but also underscores its potential to deliver impactful contributions to global healthcare advancements. As the healthcare sector continues to expand, SCNX is well-positioned to capitalize on emerging opportunities in the neurological treatment landscape.
Analyst Target Price
$1.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-30 | 2025-11-12 | 2025-08-12 | 2025-04-21 | 2025-03-26 | 2024-11-29 | 2024-07-22 | 2024-04-24 | 2024-03-25 | 2023-10-25 | 2023-07-24 | 2023-05-15 |
| Reported EPS | -0.13 | -0.19 | -0.48 | -0.3251 | -0.79 | -1.3411 | -1.304 | 20.4928 | -12.9457 | -4.571 | -2.8991 | -0.07 |
| Estimated EPS | -0.28 | 0 | None | None | 0.38 | None | None | None | None | None | -0.45 | -0.02 |
| Surprise | 0.15 | -0.19 | 0 | 0 | -1.17 | 0 | 0 | 0 | 0 | 0 | -2.4491 | -0.05 |
| Surprise Percentage | 53.5714% | None% | None% | None% | -307.8947% | None% | None% | None% | None% | None% | -544.2444% | -250% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-11 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Previous Dividend Records
| Jul 2024 | Mar 2024 | |
|---|---|---|
| Payment Date | 2024-07-24 | 2024-03-22 |
| Amount | $1.5 | $8.0 |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SCNX
2026-04-15 21:39:20
Scienture has been granted a 180-day extension by Nasdaq to regain compliance with its listing requirements. This extension provides the company with additional time to meet the necessary standards to maintain its Nasdaq listing.
2026-04-15 21:39:20
Scienture (NASDAQ: SCNX) has been granted a 180-day extension by Nasdaq to regain compliance with the minimum $1.00 bid price requirement, pushing the deadline to October 12, 2026. The company's stock will continue trading on the Nasdaq Capital Market, and Scienture highlighted recent commercial momentum, including an FDA approval for Arbli and upcoming launch of REZENOPY, to support its plan to cure the deficiency.
2026-04-15 15:10:15
Scienture has been granted a 180-day extension by Nasdaq to regain compliance with its minimum bid price requirement. This extension allows the company additional time to meet the listing standards and avoid delisting.
2026-04-07 07:10:34
Scienture Holdings, Inc. announced significant progress in its annual shareholder update, highlighting the successful FDA approval and commercial launch of Arbli™ for hypertension and the upcoming launch of REZENOPY™ for opioid overdose. The company reported a 216% increase in net revenue for 2025, driven by Arbli's initial market traction, and outlined its R&D pipeline and strategic priorities for 2026, including maximizing commercial performance and advancing pipeline candidates. Scienture also addressed its Nasdaq compliance status, indicating its intention to request an extension if needed.
2026-04-06 21:40:03
Scienture Holdings Inc. reported a significant 216% net revenue growth to $431,609 in 2025, up from $136,643 in 2024, despite a net loss from continuing operations of $41.5 million, which included a large impairment charge. The pharmaceutical company plans to launch its second product, Rezenopy, in Q2 2026, building on the recent launch of Arbli and an overall strategic shift to a focused specialty pharmaceutical business.
2026-04-06 18:10:51
Scienture Holdings, Inc. provided its annual shareholder update, highlighting significant progress in 2025 including the acquisition of REZENOPY™ and FDA approval and commercial launch of Arbli™. The company detailed strong financial performance with increased revenue and gross margin, outlined strategic priorities for 2026 focusing on maximizing commercial performance, advancing its pipeline, and scaling infrastructure, while also addressing its Nasdaq compliance status.
